Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
HCCF
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by dardadog: [QB] HUTCHINSON, Kan.--(BUSINESS WIRE)--HCCF-- HEE Corporation ('HCCF' on OTC Pink Sheets) is pleased to announce that the 8-week test of its Type II Diabetes treatment on two subjects -- Mr. Ron Brooks and Mr. Stan Casad -- has been completed, and that the results (still being analyzed by clinicians) appear to be extremely positive. The blood sugar levels for both subjects fell dramatically to levels normally seen with non-sufferers of the disease. Please see the table below that provides each test subject's daily blood sugar level readings taken throughout the 8-week trial. In summary, early indications from the recently completed phase of treatment and testing have been extremely positive, holding out great promise that a cure for Type II diabetes may be in sight. Clarification Of Stock Dividend Regarding the stock dividend declared on August 25, 2004 by Hee Corporation, the Company wishes to correct an omission that was made in the news release: The stock dividend consists of one (1) non-transferable preferred share for each common share held on the September 6, 2004 record date. Payment date of the dividend is September 15, 2004. Each common shareholder's allotment (1-for-1) of non-transferable preferred shares will automatically be mailed to all common shareholders directly from the Company's transfer agent. -0- *T TABLE OF 56-DAY TRIAL - Blood Sugar Levels Date Ron Stan ---- --- --- 6/24 231 215 Arrival 6/25 147 187 Day 1 6/26 137 157 Day 2 6/27 141 198 Day 3 6/28 110 134 Day 4 6/29 105 134 Day 5 6/30 103 122 Day 6 7/01 96 118 Day 7 7/02 96 108 Day 8 7/03 96 124 Day 9 7/04 94 146 Day 10 7/05 96 118 Day 11 7/06 94 137 Day 12 7/07 92 123 Day 13 7/08 94 105 Day 14 7/09 91 110 Day 15 7/10 91 108 Day 16 7/11 93 87 Day 17 7/12 92 98 Day 18 7/13 96 84 Day 19 7/14 94 105 Day 20 7/15 96 104 Day 21 7/16 88 115 Day 22 7/17 94 89 Day 23 7/18 96 N/A Day 24 7/19 94 102 Day 25 7/20 92 109 Day 26 7/21 96 97 Day 27 7/22 88 95 Day 28 7/23 96 114 Day 29 7/24 92 102 Day 30 7/25 94 93 Day 31 7/26 91 107 Day 32 7/27 93 80 Day 33 7/28 91 84 Day 34 7/29 92 80 Day 35 7/30 93 87 Day 36 7/31 93 84 Day 37 8/01 91 97 Day 38 8/02 93 94 Day 39 8/03 92 96 Day 40 8/04 94 94 Day 41 8/05 90 89 Day 42 8/06 91 108 Day 43 8/07 97 113 Day 44 8/08 92 133 Day 45 8/09 91 122 Day 46 8/10 89 139 Day 47 8/11 92 114 Day 48 8/12 94 120 Day 49 8/13 92 109 Day 50 8/14 93 107 Day 51 8/15 94 108 Day 52 8/16 93 112 Day 53 8/17 96 116 Day 54 8/18 88 114 Day 55 8/19 94 114 Day 56 N/A - Not available *T This ends the initial 8-week trial. Mr. Casad's levels increased at Day 43 because he had to decrease treatment due to losing a substantial amount of the treatment. His levels stayed surprisingly lower even when treatment doses were unavoidably decreased early. Both subjects have continued their normal eating habits. Results will continue to be charted, and will be incorporated into the trial's final results and conclusions. About Hee Corporation The HEE Corporation was founded for the purpose of testing and marketing a new and extremely promising homeopathic treatment for Type II Diabetes. HEE has acquired the worldwide distribution rights for this diabetic treatment. In the United States alone, 18.2 million people have diabetes and, unfortunately, 5.2 million (nearly one-third of that total) are not yet aware that they have it! Diabetes is the fifth leading cause of death by disease in the US. Now a modern-day epidemic, some 171,000,000 people around the globe are estimated to have diabetes (mostly Type II) and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. NOTE: Safe Harbor for Forward-Looking Statements--Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in the future to differ materially from forecasted results. These risks and uncertainties include, among other things, volatility of prices, product demand, market compensation and risk inherent in the company's international operations. KEYWORD: KANSAS INDUSTRY KEYWORD: BANKING BANKING MEDICAL PHARMACEUTICAL MEDICAL PHARMACEUTICAL MEDICAL PHARMACEUTICAL ALTERNATIVE MEDICINE DIVIDEND SOURCE: HEE Corporation CONTACT INFORMATION: HEE Corporation Shannon Meyer, 620-663-3333 [URL=http://www.hee-corp.com]www.hee-corp.com[/URL] [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2